Adamas Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ADMS and buy or sell other stocks, ETFs, and their options commission-free!About ADMS
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric.
CEONeil F. McFarlane
CEONeil F. McFarlane
Employees—
Employees—
HeadquartersEmeryville, California
HeadquartersEmeryville, California
Founded2000
Founded2000
Employees—
Employees—
ADMS Key Statistics
Market cap376.37M
Market cap376.37M
Price-Earnings ratio-4.85
Price-Earnings ratio-4.85
Dividend yield—
Dividend yield—
Average volume964.73K
Average volume964.73K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$9.15
52 Week high$9.15
52 Week low$4.02
52 Week low$4.02
Stock Snapshot
Adamas Pharmaceuticals(ADMS) stock is priced at $8.22, giving the company a market capitalization of 376.37M. It carries a P/E multiple of -4.85.
Adamas Pharmaceuticals(ADMS) stock opened on 2025-11-07 at —. The price climbed to — and dipped to —.
The Adamas Pharmaceuticals(ADMS)'s current trading volume is 0, compared to an average daily volume of 964.73K.
In the last year, Adamas Pharmaceuticals(ADMS) shares hit a 52-week high of $9.15 and a 52-week low of $4.02.
In the last year, Adamas Pharmaceuticals(ADMS) shares hit a 52-week high of $9.15 and a 52-week low of $4.02.
People also own
Based on the portfolios of people who own ADMS. This list is generated using Robinhood data, and it’s not a recommendation.